News & Events zu Alphatec Holdings, Inc. (ATEC)ATECAlphatec Holdings, Inc.

Major Averages Rebound as Oil Prices Retreat

The major averages were sharply higher near noon, curtailing some of this week's declines after four straight down sessions. The rebound comes as oil prices retreat roughly 3% from their recent highs, easing some of the inflation pressure that has pushed Treasury yields to multiyear highs.The August consumer price index report came in roughly in-line with expectations, with headline consumer prices rising 0.4% month over month and 3.4% from a year earlier, while core CPI increased 0.3% monthly and 2.4% annually. The firmer-than-expected core reading suggests underlying inflation remains sticky.Markets are now pricing a high probability of a 25-basis-point Fed hike next week, a dramatic change from the expectations for rate cuts that dominated the market earlier in the summer. The 10-year Treasury yield is hovering around 4.94%-4.96%, while the 30-year yield recently reached its highest level since 2004.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Oracleprovided areport for Q1Adobealso provided areport for Q3CopartACV Auctionsfor $10.50 per share in cash, representing an implied equity value of approximately $1.9BKrogerreportedand reiterated its FY26 adjusted earnings guidanceOpenAI CEO Sam Altman told staff the company could slow down the development of AI,2. WALL STREET CALLS:NuScale Power (SMR)to Sell from Neutral at UBSJPMorganChewyto Neutral, citing pressure on organic growthBarringtonCopartto Outperform from Market PerformInternational Paperto Buy at BofA following pullbackBernsteincoverage of Shopify (SHOP) with an Outperform rating3. AROUND THE WEB:Colgate-Palmoliveis weighing a sale of certain mass-market personal care brands, including Softsoap, Irish Spring, and Speed Stick, and is working with Goldman Sachson the process, Reuters reportsElon Musk's SpaceXhas filed a lawsuit against Texas Attorney General Ken Paxton and Grimes County, Texas in an effort to prohibit the release of records related to tax breaks the company received for Terafab, the semiconductor facility it is building near Houston, Business Insider saysNovartisinvestors will be increasing their scrutiny of the company's dealmaking strategy following setbacks to drugs acquired through mergers and acquisitions, Reuters reportsAlibabais set to lead a $300M investment in UniPat AI, valuing the company at $2.5B, Bloomberg reportsNvidiais facing DOJ scrutiny over whether its $17B non-exclusive Groq licensing deal and hiring of key executives were structured to avoid antitrust review, NY Times says4. MOVERS:Celesticagains in New York after announcing Chawla will assume the, global markets, and Ankenmann will succeed him as chief financial officerAlphatecincreases after itsDell Technologieshigher after RBC Capitalof the stock with an Outperform ratingOklofalls after entering into anfor up to $1BTenablelower after pricing itsof senior notes5. EARNINGS/GUIDANCE:RH, provided guidance for Q3, and narrowed its outlook for FY26Ibex, with CEO Bob Dechant calling it a "record-breaking quarter"Zumiez, with EPS and revenue missing consensusReformationand provided guidance for FY26MoneyHero, with EPS and revenue lower year-over-yearINDEXES:Near midday, the Dow was up 508.39, or 0.98%, to 52,572.49, the Nasdaq was up 304.74, or 1.17%, to 26,386.46, and the S&P 500 was up 76.82, or 1.01%, to 7,668.52.

Company Reaffirms FY2026 Revenue Outlook, Raises EBITDA Guidance to $140 Million

The Company is reaffirming its full-year revenue outlook and increasing adjusted EBITDA guidance following a second quarter characterized by strong case volume growth, continued surgeon adoption, expanding profitability, and positive free cash flow generation. For fiscal year 2026, the Company continues to expect total revenue of approximately $882 million, including approximately $805 million of surgical revenue and approximately $77 million of EOS revenue. This outlook represents approximately 15% total revenue growth and approximately 17% surgical revenue growth for the year. The Company now expects adjusted EBITDA of approximately $140 million, an increase from its prior expectation of approximately $134 million, reflecting continued progress in operating leverage and margin expansion. The Company also continues to expect at least $20 million of free cash flow for fiscal year 2026.